VS-041 for HFpEF
phase 1Treat heart failure with preserved ejection fraction by targeting extracellular matrix remodeling, cardiac fibrosis, and MMP-2/MMP-9 activity associated with cardiovascular aging.
Narrow-spectrum matrix metalloproteinase inhibitor targeting MMP-2 and MMP-9; evaluated in Phase 1 safety/tolerability studies and a Phase 1c proof-of-mechanism biomarker trial in HFpEF participants.
ClinicalTrials.gov record for a safety, tolerability, and biomarker trial of VS-041 in participants with HFpEF, published 2025-11-04; 2026 materials describe Phase 1 safety/tolerability and Phase 1c proof-of-mechanism trial design.
Company-listed 2025 presentation reports target engagement and that VS-041 was safe and well tolerated in healthy participants; 2024 poster reports inhibition of cardiac fibrosis and pro-fibrotic collagen hormone endotrophin.